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sleep apnea. There is a growing body of evidence revealing diverse functions beyond 
the conventional tasks of different organs such as carotid body and gut microbiota. 
Chronic	intermittent	hypoxia	and	sleep	loss	due	to	sleep	fragmentation	are	associated	
with	 insulin	 resistance.	 Indeed,	 carotid	 body	 is	 a	multi-	sensor	 organ	 not	 sensoring	
only	hypoxia	and	hypercapnia	but	also	acting	as	a	metabolic	 sensor.	The	emerging	
evidence shows that obstructive sleep apnea and particularly chronic intermittent 
hypoxia	is	associated	with	non-	alcoholic	fatty	liver	disease.	Gut	dysbiosis	seems	to	be	
an important factor in the pathophysiology of obstructive sleep apnea and its conse-
quences.	The	impact	of	sleep	fragmentation	and	intermittent	hypoxia	on	the	develop-
ment of metabolic syndrome may be mediated via altered gut microbiota. Circadian 




tive	 sleep	 apnea	 independently	predicts	 impaired	 lipid	 levels.	 This	mini-	review	will	
provide novel insights into the mechanisms of metabolic dysfunction in obstructive 
sleep	apnea	combining	recent	evidence	from	basic,	translational	and	clinical	research,	
and discuss the impact of positive airway pressure treatment on metabolic disorders.
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somnographic findings in the general population gave an estimated 





Chronic	 intermittent	 hypoxia	 and	 sleep	 loss	 due	 to	 SF	 are	 as-
sociated	with	 insulin	 resistance	 (Tasali	 et	 al.,	 2008)	 and	metabolic	
dysfunction	(Olea	et	al.,	2014;	Ryan	et	al.,	2019;	Sacramento	et	al.,	
2016;	 Shin	 et	 al.,	 2014).	 Recently,	 adipose	 tissue	 dysfunction	 has	
been	suggested	 to	play	a	key	 role	 in	dysmetabolism	 in	OSA	 (Ryan	
et	 al.,	 2019).	 There	 is	 a	 growing	 body	 of	 evidence	 that	 OSA	 and	
particularly	CIH	is	associated	with	non-	alcoholic	fatty	liver	disease	








suggested	 to	 contribute	 to	 a	 variety	 of	 disorders.	 Sleep	 loss,	 SF	
and	CIH	have	been	linked	with	gut	dysbiosis	(Benedict	et	al.,	2016;	






of	metabolic	 dysfunction	 in	OSA	combining	 recent	 evidence	 from	
basic,	translational	and	clinical	research,	and	paving	the	way	to	new	
research	 questions,	 treatment	 options	 and	 precision	medicine	 for	
OSA.
2  |  METABOLIC COMORBIDITIES 
A SSOCIATED WITH OSA
The	 relationship	 between	 OSA	 and	 metabolic	 disease	 is	 une-
quivocal.	If	on	one	hand,	sleep	apnea	results	in	intermittent	hy-
poxia	(IH)	and	SF	leading	to	and	exacerbating	obesity,	metabolic	
syndrome	 and	 type	 2	 diabetes	 (T2D;	 Bonsignore	 et	 al.,	 2013;	
Conde	 et	 al.,	 2014)	 and	NAFLD	 (Jin	 et	 al.,2018);	 on	 the	 other	
hand,	obesity	is	considered	a	major	risk	factor	for	the	develop-
ment	 and	progression	of	OSA	 (Bonsignore	 et	 al.,	 2013;	Conde	
et	al.,	2014).
2.1  |  Metabolic syndrome and T2D
Obstructive sleep apnea is independently associated with metabolic 
syndrome	or	its	core	components	that	incorporate	visceral	obesity,	
hypertension,	 insulin	 resistance,	 glucose	 intolerance	 and	 dyslipi-
daemia	(Bonsignore	et	al.,	2013;	Conde	et	al.,	2014).	While	the	link	
between	OSA	and	some	of	 the	pathological	 features	of	metabolic	
syndrome,	 such	 as	 daytime	 hypertension,	 was	 highly	 cemented,	














T2D	 in	1,206	Chinese	 adults	 in	Hong	Kong	 from	2006	and	2013,	
where	the	authors	found	that	OSA	severity	independently	predicted	
incident	diabetes	and	that	there	were	no	interactions	between	OSA	
and	obesity	 (Xu	et	 al.,	 2019).	Also,	 in	 a	 cross-	sectional	 analysis	 of	
5,294	 participants	 of	 the	 multi-	national	 European	 Sleep	 Apnoea	
Cohort	 (European	 Sleep	 Apnoea	Database,	 ESADA),	 it	 was	 found	
that	OSA	severity	independently	predicts	glycaemic	health	in	non-	














resistance	 in	 patients	 with	 OSA	 are	 not	 consensual.	 CPAP	 treat-





2	 and	 4	 years,	 found	 that	CPAP	 therapy	 did	 not	 affect	 glycaemic	
control in those with diabetes or prediabetes or diabetes risk over 
standard-	of-	care	 treatment	 (Loffler	 et	 al.,	 2020).	 However,	 this	
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study	was	not	primarily	dedicated	to	evaluate	the	 impact	of	CPAP	






cated to usual care that showed a deterioration in glycaemic control 
during	follow-	up	(Loffler	et	al.,	2020).	This	clearly	points	towards	the	
existence	of	 sex	differences	 in	 the	 link	between	OSA	and	dysme-
tabolism that deserves further clarification.





presence	 of	 confounding	 factors,	 such	 as	 obesity,	 among	 others.	
These discrepancies among studies clearly indicate that more re-
search	on	the	effects	of	CPAP	and	on	the	link	between	OSA	and	dys-
metabolism are needed to elucidate pathophysiological mechanisms. 
Research	in	animal	models	of	CIH,	that	mimic	OSA	-	particularly	in	
rodents,	has	allowed	the	knowledge	on	the	mechanisms	behind	the	
association	 between	OSA	 and	metabolic	 diseases	 to	 deepen.	 CIH	
and	sleep	loss	due	to	SF	are	two	pathological	characteristics	of	OSA,	
and	both	are	associated	with	 insulin	resistance	(Tasali	et	al.,	2008)	
and	 metabolic	 dysfunction	 (Olea	 et	 al.,	 2014;	 Ryan	 et	 al.,	 2019;	
Sacramento	et	al.,	2016;	Shin	et	al.,	2014).	Whereas	the	effects	of	
CIH	on	insulin	sensitivity	are	consensual	with	several	authors	show-
ing	 that	 CIH	 induces	 alterations	 in	 insulin	 secretion	 (Sacramento	















However,	 metabolic	 dysfunction	 is	 known	 to	 be	 present	 in	 lean	
OSA	subjects	(Pamidi	et	al.,	2012),	and	in	CIH	rodent	models	with-
out	the	obesity	component	(Carreras	et	al.,	2012;	Fenik	et	al.,	2012;	
Sacramento	et	 al.,	 2016;	 Shin	et	 al.,	 2014;	Wang	et	 al.,	 2013)	 and	
without	alterations	in	the	fat	depots	(Olea	et	al.,	2014;	Sacramento	
et	al.,	2016).	Therefore,	we	can	conclude	that	in	OSA,	obesity	is	not	
the	only	 factor	contributing	 to	metabolic	dysfunction	and,	 in	 fact,	




deregulation	 of	 the	 hypothalamus–	pituitary	 axis,	 generation	 of	
reactive	 oxygen	 species	 (ROS;	 Tasali	 et	 al.,	 2008),	 alteration	 in	
adipokine	 levels	 (Olea	 et	 al.,	 2014;	 Reinke	 et	 al.,	 2011)	 and	 in-
flammation	of	the	adipose	tissue	(Almendros	et	al.,	2015;	Murphy	
et	al.,	2017;	Reinke	et	al.,	2011;	Thorn	et	al.,	2017).	In	fact,	more	
recently the hypothesis that adipose tissue dysfunction is a 
major	contributor	for	dysmetabolism	in	OSA	has	gained	attention	
(Ryan	 et	 al.,	 2019).	 Adipose	 tissue	 inflammation,	 characterized	
by	 infiltration	 of	 macrophages	 and	 increased	 secretion	 of	 pro-	
inflammatory	cytokines,	was	observed	in	lean	CIH	rodent	models	
(Almendros	et	al.,	2015;	Murphy	et	al.,	2017;	Reinke	et	al.,	2011)	
and	 in	 isolated	 human	 adipocytes	 (Murphy	 et	 al.,	 2017;	 Taylor	
et	 al.,	 2014).	 Apart	 from	 inflammation,	 hypoxia	 was	 also	 sug-
gested	to	be	involved	in	adipose	tissue	dysfunction;	however,	the	
data are not consensual. Whereas some authors found that lean 
mice	exposed	to	CIH	exhibit	visceral	adipose	tissue	dysfunction	
via	activation	of	hypoxia-	inducible	factor	(HIF;	Gozal	et	al.,	2017)	
and	 that	 increased	 expression	 of	 HIF-	1α in this tissue is asso-
ciated with decreased insulin signalling and sensitivity (Thomas 
et	al.,	2017),	others	found	that	CIH	 induced	whole-	body	 insulin	
resistance with a decrease in visceral adipose tissue insulin sig-
nalling	but	with	no	alterations	in	HIF-	1α and 2α	(Sacramento	et	al.,	





in	 BMI-	matched	 controls	 despite	 lower	 mean	 daytime	 arterial	
oxygen	 saturation.	 Another	 contributor	 within	 the	 adipose	 tis-
sue that could also be involved in dysmetabolism is the altered 
secretion	of	adipokines,	leptin	and	adiponectin	(Olea	et	al.,	2014;	
Pierard	 et	 al.,	 2019;	 Thorn	 et	 al.,	 2017).	CIH	 is	 associated	with	
increased	 leptin	 levels	 (Olea	 et	 al.,	 2014;	 Pierard	 et	 al.,	 2019).	









ifies	 adiponectin	 oligomerization	 as	 well	 as	 the	 expression	 of	





tabolism	 (Berger	 &	 Polotsky,	 2018;	 Gileles-	Hillel	 et	 al.,	 2017;	
Olea	et	al.,	2014).	CIH	in	rats	induces	a	whole-	body	oxidative	sta-
tus	manifested	by	an	 increase	 in	 lipid	peroxides	and	diminished	
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activities	of	superoxide	dismutase	(Olea	et	al.,	2014)	and,	in	the	
visceral	adipose	tissue,	CIH–	metabolic	dysfunction	is	associated	
with increased ROS production and alterations in the electron 
transport	 chain	 (Gileles-	Hillel	 et	 al.,	 2017).	 Altogether,	 we	 can	
conclude that adipose tissue dysfunction plays a role in the link 
between	 CIH	 and	 dysmetabolism,	 but	 is	 probably	 not	 the	 only	
or	the	main	trigger	initiating	a	dysmetabolic	state.	For	example,	
pancreatic β-	cells	are	particularly	sensitive	to	hypoxia	(Pallayova	






ity	 that	 can	 contribute	 to	metabolic	 dysfunction	 (Conde	 et	 al.,	
2014,	2017).	Therefore,	we	can	say	that	more	studies	in	this	field	
are needed to provide a better understanding of the mechanisms 
involved	in	the	link	between	OSA	and	metabolic	diseases.
2.2  |  Non- alcoholic fatty liver diseases
Non-	alcoholic	fatty	liver	diseases	is	now	the	most	common	liver	dis-
ease	in	the	world,	accounting	for	25%	of	the	worldwide	population.	













2016;	 Aron-	Wisnewsky	 &	 Pepin,	 2015;	 Mirrakhimov	 &	 Polotsky,	
F I G U R E  1 Postulated	mechanisms	







or indirectly at the pancreas and 
in the adipose tissue to promote a 









pancreas. This generates a vicious cycle 
CIH–	CB–	SNS–	metabolic	dysfunction	
that leads to metabolic diseases such 
as	obesity,	type	2	diabetes	(T2D)	and	
metabolic syndrome
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2012).	 Enormous	 evidences	 have	 come	 from	 studies	 in	 animals	









hepatitis	and	 liver	 fibrosis	 (Aron-	Wisnewsky	et	al.,	2012;	Polotsky	
et	al.,	2009;	Qi	et	al.,	2015).	The	link	between	OSA	and	NAFLD,	apart	
from	being	present	in	adults,	was	also	found	to	be	present	in	obese	
children	 (Alkhouri	 et	 al.,	 2015;	Nobili	 et	 al.,	 2015),	 and	 associated	




ers	do	not	 (Jullian-	Desayes	et	 al.,	 2016;	Kohler	&	Stradling,	2016;	













despite significant correlations between hepatic steatosis and mark-
ers	of	severity	of	OSA,	CPAP	alone	did	not	improve	hepatic	steatosis	
and	fibrosis	(Ng	et	al.,	2021).	These	controversial	data	highlight	that	
more	 studies	are	needed	 to	 clearly	define	 the	 impact	of	CPAP	on	
NAFLD	and	its	progression	as	well	as	the	population/disease	stage	




proposed	for	 the	 link	between	OSA	and	T2D.	Namely,	 it	 is	known	
that	OSA	 generates	metabolic	 dysfunction	 (see	 previous	 section),	
contributing	 to	 the	development	of	obesity	and	 insulin	 resistance,	
which	are	pathological	features	associated	with	NAFLD	(Bonsignore	
et	 al.,	 2013;	 Conde	 et	 al.,	 2014).	 Additionally,	 other	 mechanisms,	
such	 as	 the	 increased	 expression	 of	 genes	 involved	 in	 lipogenesis	
via	 the	HIF-	1α	 pathway;	 the	 increased	expression	of	 lysyl	 oxidase	
enzyme,	a	protein	involved	in	the	rigidity	of	extracellular	matrix;	an	
increased	oxidative	stress	and	lipid	peroxidation;	the	increased	mito-
chondrial dysfunction; the increased liver sympathetic nervous sys-
tem activity; and the increased intestinal permeability and disruption 
of	the	gut–	liver	axis	 (Aron-	Wisnewsky	et	al.,	2016;	Mirrakhimov	&	
Polotsky,	2012)	might	be	involved	in	liver	injury	and	progression	to	
more severe disease states.
3  |  SLEEP AND MICROBIOTA
Although	 Hippocrates	 had	 already	 suggested	 the	 association	 be-
tween	diseases	and	sleep,	the	first	systematic	studies	of	the	effects	
of a bacterial infection on sleep were not done until about 30 years 
ago	 (Toth	&	Krueger,	1988,	1989).	They	demonstrated	 that	bacte-
rial	 infection	 initially	 increases	 non-	rapid	 eye	 movement	 (NREM)	
sleep	followed	by	an	inhibition	in	NREM	sleep.	Rapid	eye	movement	
(REM)	sleep	is	inhibited	during	infections.	Further,	depletion	of	gut	






dances	 of	 the	 families	 Coriobacteriaceae	 and	 Erysipelotrichaceae,	
and	lower	abundance	of	Tenericutes,	previously	all	associated	with	
metabolic	perturbations	in	animal	or	human	models	(Benedict	et	al.,	
2016).	 Fasting	 and	 postprandial	 insulin	 sensitivity	 decreased	 after	
PSD	versus	NS	(Benedict	et	al.,	2016).	Chronic	SF	 in	mice	particu-
larly	promoted	the	growth	of	Lachnospiracae	and	Ruminococcacae	
families,	 with	 contrasting	 decreases	 in	 Lactobasiaceae	 and	
Bifidobacteriaceae	 families	 that	consist	of	many	beneficial	 species	
(Poroyko	et	al.,	2016).	Indeed,	the	impact	of	SF	on	the	development	
of metabolic syndrome may be mediated by altered gut microbiota 
(Poroyko	et	 al.,	 2016).	 These	 findings	 suggest	 that	metabolic	 dys-
function associated with sleep loss may in fact be mediated through 
the overgrowth of specific gut bacteria.




by	 lower	microbial	 richness	 and	diversity,	 depletion	of	 anaerobes,	
and	 short-	chain	 fatty	 acid-	producing	 bacteria	 (Li	 et	 al.,	 2020).	
Lachnospira	 and	 Bacteroides	 were	 signature	 bacteria	 in	 patients	
with	acute	 insomnia,	while	Faecalibacterium	and	Blautia	were	sig-
nature bacteria for distinguishing chronic insomnia patients from 
healthy controls. These signature bacteria were also associated with 
patients'	self-	reported	sleep	quality	and	plasma	IL-	1β	(Li	et	al.,	2020).	
CIH,	 a	 characteristic	 of	OSA,	 leads	 to	 disrupted	 gut	microbiota	 in	
mice	 (Moreno-	Indias	et	al.,	2015).	 In	guinea	pigs,	exposure	 to	CIH	
alters	 gut	microbiota	 richness	 and	 composition,	 brainstem	 neuro-
chemistry,	and	autonomic	control	of	heart	rate,	independent	of	CB	
sensitization,	 suggesting	 modulation	 of	 breathing	 and	 autonomic	
homeostasis	via	 the	microbiota–	gut–	brainstem	axis	 (Lucking	et	al.,	
2018).
It would be appealing to improve sleep quality by modifying gut 
microbiota with probiotics. The data addressing this issue are still 
scarce.	In	a	study	of	32	students,	the	administration	of	the	probiotic	
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Lactobacillus	gasseri	CP2305	markedly	improved	sleep	quality	mea-
sured	 by	 the	Pittsburgh	 Sleep	Quality	 Index	 (PSQI;	Nishida	 et	 al.,	
2017).	 Concomitantly,	 the	 relative	 abundance	 of	 15	 gut	microbial	
species	differed	between	the	control	and	probiotic	groups,	 includ-
ing	decreases	in	Bact.	Vulgatus	and	increases	in	Dorea	Longicatena	
following	 probiotic	 use.	 Another	 double-	blind	 randomized	 con-
trolled	 trial	 found	that	daily	use	of	a	probiotic	mixture	 (containing	
Lactobacillus	 fermentum	 LF16,	 Lactobacillus	 rhamnosus	 LR06,	
Lactobacillus	plantarum	LP01	and	Bifidobacterium	longum	BL04)	in	
young	healthy	participants	 led	to	 improvement	 in	PSQI	score	over	
time,	 although	 PSQI	 scores	 did	 not	 differ	 from	 those	 of	 controls	
(Marotta	et	al.,	2019).
4  |  CIRC ADIAN MISALIGNMENT, OBESIT Y 
AND MICROBIOTA
Circadian rhythm is the rhythm that is driven internally (i.e. by the 
endocrine	system)	and	controlled	by	the	central	clock	located	in	the	
suprachiasmatic nucleus. When this rhythm is entrained by environ-
mental	factors	(e.g.	time	zeitgebers),	it	is	called	the	diurnal	rhythm.	
The	two	rhythms	are	interrelated,	and	circadian	rhythms	are	usually	
synchronized	 to	 environmental	 cues.	There	 is	 some	evidence	 that	
bacterial cells have their clocks that oscillate in a determined rhythm 
based	on	 specific	 factors,	whether	 related	 to	 the	host	 or	 the	 sur-
rounding	environmental	factors	(Mashaqi	&	Gozal,	2020).
The	role	of	circadian	misalignment	in	OSA	is	unclear.	However,	
both	 SF	 (Poroyko	 et	 al.,	 2016)	 and	 short	 sleep	duration	 (Benedict	
et	 al.,	 2016)	 are	 associated	with	 gut	 dysbiosis,	which	may	 be	 due	
to	 activation	 of	 the	 hypothalamic–	pituitary–	adrenal	 (HPA)-	axis.	
Metabolic disturbances associated with sleep loss may in fact be 
mediated	through	the	overgrowth	of	specific	gut	bacteria	(Benedict	
et	al.,	2016).	Reciprocally,	the	end-	products	of	bacterial	species	that	
grow in response to sleep loss are able to induce fatigue (Zielinski 
et	al.,	2013).	Inter-	tissue	circadian	misalignment	occurs	also	with	IH	
(Manella	et	al.,	2020),	a	typical	feature	of	OSA.	This	means	that	there	




potentiate	 the	 cardiometabolic	 risk	 of	 patients	 with	 OSA	 (Santos	
et	al.,	2020).
A	meta-	analysis	of	shift	work	showed	an	increased	risk	of	obe-
sity	 both	 in	 cross-	sectional	 and	 follow-	up	 cohort	 studies,	 espe-
cially	in	developing	abdominal	obesity	(Sun	et	al.,	2018).	Not	only	
the food content but also the timing of food intake is crucial for 







energy	 expenditure	 through	 non-	shivering	 thermogenesis	 (Li	
et	al.,	2017).
5  |  OSA AND MICROBIOTA








result in gut epithelial barrier dysfunction triggering both local and 
systemic	inflammatory	responses.	Thus,	all	tissues	and	organs	of	the	
host	could	be	affected,	promoting	cognitive/mood	alterations	and	
cardiovascular or metabolic diseases.
Regarding	 IH,	 a	 recent	work	 carried	 out	 in	 rats	 has	 described	
that	 application	 of	 IH	 similar	 to	 that	 experienced	 in	 patients	with	
OSA	 is	 translated	 into	 the	gut	 lumen	 (Moreno-	Indias	et	 al.,	2015).	
Specifically,	the	oxygenation	was	locally	measured	using	an	oxygen	
microelectrode.	 These	 measurements	 revealed	 that	 IH,	 although	
progressively	attenuated	in	amplitude,	is	translated	further	into	the	
lumen,	at	 least	until	200	µm.	Furthermore,	animals	exposed	 to	 IH	
showed a different gut microbiota composition in comparison to 
controls	 (Moreno-	Indias	et	al.,	2015).	 Interestingly,	 the	 IH-	induced	
alterations	are	quite	persistent:	after	a	6-	week	period	of	 recovery	
by	 normal	 breathing,	 the	 differences	 in	 microbiota	 composition	
remained	 in	 a	 principal	 component	 analysis	 (Moreno-	Indias	 et	 al.,	
2016).	More	recent	data	also	show	that	IH-	induced	changes	in	gut	
microbiota	are	able	to	elicit	sleep	alterations	 (Badran	et	al.,	2020).	
This finding was revealed by measuring sleep recording in the fae-





imental	 study,	 mice	 were	 subjected	 to	 a	 realistic	 paradigm	 of	 SF	
mimicking	OSA	(Poroyko	et	al.,	2016).	The	authors	found	that	this	
challenge can modify the gut microbiota resulting in adipose tissue 
inflammation	and	metabolic	alterations.	Animals	subjected	to	SF	ex-
hibited	an	increased	visceral	fat	mass	after	4	weeks	of	exposure,	and	








changes that SF induce in the microbiota can be translated to im-
portant metabolic features.
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Very	 limited	 information	 is	 available	 from	 clinical	 studies	 to	
date.	In	a	recent	work,	the	authors	found	significant	differences	at	
the	general	 level	microbiota,	particularly	when	comparing	controls	
and	 severe	OSA	 (Ko	et	 al.,	 2019).	 The	differences	were	more	evi-
dent	when	looking	at	specific	microbe	type,	for	instance	Prevotella.	
In	 another	 study,	 carried	out	on	 an	 animal	model	 based	on	upper	
airway	obstructions,	application	of	OSA	significantly	increased	sys-
tolic	blood	pressure	at	7	and	14	days	(Ganesh	et	al.,	2018).	The	main	
novelty of this study was that such hypertensive alteration can be 
abolished by the probiotic Clostridium butyricum or the prebiotic 
Hylon	VII.	Therefore,	solid	experimental	data	and	preliminary	clin-
ical results are available on the role that the gut microbiota plays 
in	OSA.	Figure	2	depicts	how	gut	microbiota	alterations	induced	by	
OSA	components	could	mediate	cardiovascular	and	metabolic	con-
sequences. Our current knowledge on the topic clearly deserves fur-
ther basic and clinical research.
6  |  CEREBR AL METABOLISM AND OSA
The harmful effect of disturbed sleep on brain health is particularly 
evident	 in	 patients	with	OSA.	Both	 IH	 and	SF	due	 to	OSA	 condi-
tions may concur altering brain homeostasis and producing cerebral 
inflammation,	 cognitive	 deterioration,	 neuropsychological	 distur-
bances and cerebrovascular dysfunction. There is growing evidence 
that brain functional state and energetics are mutually related 
(Shulman,	 2011);	 it	 is	 remarkable	 that	 glutamate	 and	ATP,	 as	well	
as	 glucose,	 lactate	 and	 other	metabolites,	 are	molecules	 involved	
in	cerebral	cellular	metabolism,	but	also	have	signalling	functions	in	
the	 brain	 (DiNuzzo,	 2016).	 In	 particular,	 glucose	 and	 glycogen	 ca-
tabolism,	though	aerobic	glycolysis,	features	wakefulness;	whereas	
lactate	brain	levels	decrease,	characterizing	the	transition	to	sleep;	
moreover,	 lower	 lactate	 levels	 during	 sleep	 represent	 the	 effect	
of decreased glucose production and increased glymphatic clear-
ance	 (Aalling	 et	 al.,	 2018).	Accordingly,	mouse	model	 studies	 sug-
gested	 that	 extracellular	 lactate	 concentrations	 may	 be	 a	 reliable	
sleep– wake biomarker. This evidence was reached by observing 
that persistent and sustained decreases in brain lactate levels were 
documented	 in	mice	 during	 sleep,	whereas	 elevated	 lactate	 levels	
were present from awakening and maintained throughout prolonged 
wake	(Naylor	et	al.,	2012).
The	measurement	of	cerebrospinal	fluid	(CSF)	lactate	levels	can	
reflect the brain glucose metabolism (in combination with pyruvate 
levels),	which	can	also	be	measured	by	 the	2-	deoxy-	2-	(18F)-	fluoro









ative processes due to the privation of the positive effects of sleep 
quality	and	continuity	on	brain	health.	 In	particular,	 the	beneficial	
effect of sleep related to glymphatic system activity can be sup-
pressed	by	OSA	with	the	accumulation	of	brain	catabolic	products	
interfering	with	neuronal	functioning	(Figure	3).	Moreover,	hypoxia	
can trigger neurodegenerative processes by inducing β-	amyloid	
plaque	formation	and	neuronal	damage	(Shiota	et	al.,	2013).
Cortical	 brain	 glucose	 consumption	 can	 be	measured	 by	 [18F]
FDG	PET	(Liguori	et	al.,	2016),	a	widely	diffuse	tool	to	evaluate	and	










function corresponded to β-	amyloid	plaque	deposition	(André	et	al.,	
2020).	These	findings	reinforce	the	evidence	that	OSA	can	promote	
and accelerate neurodegenerative processes in adults and the el-
derly	(Liguori,	Mercuri,	et	al.,	2019;	Liguori	&	Placidi,	2018).	Notably,	





Liguori	&	Placidi,	 2018).	 In	 agreement	with	 this	 suggestion,	 short-	
term	CPAP	treatment	 induces	modest	changes	 in	cerebral	glucose	
metabolism	in	patients	with	OSA;	briefly,	it	has	been	demonstrated	





F I G U R E  2 Gut	microbiota	alterations	induced	by	obstructive	
sleep	apnea	(OSA)	components	could	mediate	some	of	its	
associated cardiovascular and metabolic consequences
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consumption,	 promoting	 inflammation,	 and	 inducing	 neurodegen-
erative	 processes.	 Hypoxia	 and	 SF	 are	 the	 two	 main	 detrimental	
factors	involved	in	this	relation.	CPAP	can	represent	a	reliable	treat-
ment for ensuring the physiological brain metabolism in patients 
with	OSA,	although	novel	and	clear	evidence	should	be	achieved	to	
reinforce this suggestion.
7  |  CB, IH AND METABOLISM
The	CBs	are	arterial	chemoreceptors	that	classically	sense	and	re-
spond to changes in arterial blood O2,	CO2	and	pH	levels.	Besides	
their	role	in	the	control	of	ventilation,	the	CBs	have	been	described	
as	metabolic	sensors	involved	in	energy	homeostasis	(Conde	et	al.,	





and	 carotid	 sinus	nerve	 (CSN)	denervation	 (Fletcher	 et	 al.,	 1992a;	
Prabhakar	et	 al.,	 2005).	More	 recently,	 the	CB	has	been	also	pro-
posed	to	be	one	of	the	 links	between	CIH	and	metabolic	dysfunc-
tion.	 Supporting	 this	 link,	 CB	 denervation	 prevented	CIH-	induced	
fasting	 hyperglycaemia	 and	 hepatic	 glucose	 output	 (Shin	 et	 al.,	
2014).	Additionally,	 the	Conde	group	has	described	 that	 the	CB	 is	




glucose	 uptake	 in	 insulin-	sensitive	 tissue	 –	 induced	 by	 the	 hyper-
caloric	 diets	 in	 rats	 (Ribeiro	 et	 al.,	 2013;	 Sacramento	 et	 al.,	 2017,	
2018).	Also,	they	found	that	abolishment	of	CB	activity	normalized	
the heightened sympathetic activity observed in these animal mod-
els	 (Cracchiolo	et	al.,	2019;	Sacramento	et	al.,	2017),	meaning	that	





Guimaraes	et	al.,	2020),	 and	postulated	 that	 insulin,	 leptin	and	 in-
flammatory	cytokines,	which	are	known	to	act	on	the	CB	and	whose	
levels	are	deregulated	in	OSA	and	metabolic	disease,	contribute	to	
the	 vicious	 cycle	 of	 CIH–	CB	 activation–	metabolic	 disease	 (Conde	
et	al.,	2017,	2018;	Sacramento	et	al.,	2020).	Therefore,	 it	could	be	
postulated	 that	CIH,	by	acting	on	 the	CB	directly	or	 indirectly	via	
altering insulin secretion by the pancreas or the increasing leptin and 
inflammation	in	the	adipose	tissue,	lead	to	an	increase	in	CB	chemo-
sensitivity	that	promotes	metabolic	dysfunction	(Figure	1).
8  |  DYSLIPIDAEMIA AND OSA




defined as abnormally elevated total cholesterol or triglycerides 
with	or	without	a	corresponding	significantly	reduced	high-	density	
F I G U R E  3 Intermittent	hypoxia	
(IH)	and	sleep	fragmentation	(SF)	can	
negatively influence brain glucose 
metabolism and induce glymphatic 
system malfunction in patients with 
obstructive	sleep	apnea	(OSA);	as	a	
result,	brain	2-	deoxy-	2-	(18F)-	fluoro-	d-	
glucose positron emission tomography 
([18F]FDG	PET)	shows	the	reduction	of	
cerebral glucose metabolism indicative of 
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lipoprotein	(HDL)	level,	is	associated	with	progressive	atherosclero-
sis. There is an increased risk of cardiovascular morbidity and mortal-
ity	in	patients	with	sleep	apnea	with	high	lipid	levels,	and	especially	
in	 the	 ones	with	 other	 risk	 factors	 like	 obesity,	 diabetes,	 physical	
inactivity,	and	a	high-	cholesterol	diet	(Seetho	et	al.,	2014).
The	role	of	OSA	in	the	development	of	dyslipidaemia	has	been	
investigated in animal models and clinical studies for evaluation of 
an	independent	relationship	beyond	the	effects	of	obesity.	Although	




that	 may	 promote	 dyslipidaemia	 (Adedayo	 et	 al.,	 2014;	 Barros	 &	
García-	Río,	2019).	Evidence	from	animal	models	of	OSA	has	shown	
that	CIH	 induces	 fasting	dyslipidaemia	even	 in	 lean	mice	 (Li	et	al.,	
2005),	and	mice	exposed	to	CIH	and	a	high-	cholesterol	diet	devel-
oped	 atherosclerotic	 lesions	 in	 the	 aorta,	 and	 progression	 of	 dys-
lipidaemia	(Savransky	et	al.,	2007).	The	clinical	evidence	supporting	
the	 impact	 of	OSA	 on	 lipid	metabolism	 is	mostly	 based	 on	 cross-	
sectional	studies.	Even	so,	OSA	has	been	shown	to	be	independently	




et	 al.,	 2017),	 lipid	 levels	 are	 higher	 in	 particular	 in	 OSA	 patients	
with	central	obesity,	as	shown	in	the	 large	multicentre	ESADA	co-
hort	 (Gunduz	 et	 al.,	 2018).	 A	 meta-	regression	 analysis	 including	





Continuous	positive	 airway	pressure	 is	 the	 first-	line	 treatment	
for	OSA,	but	it	is	unclear	whether	CPAP	treatment	can	improve	dys-
lipidaemia and reduce cardiovascular morbidities in patients with 
OSA.	 In	 a	 meta-	regression	 analysis	 (Nadeem	 et	 al.,	 2014),	 it	 was	
shown	that	CPAP	treatment	 improves	dyslipidaemia	by	decreasing	
total	 and	 LDL-	cholesterol,	 and	 increasing	 HDL-	cholesterol	 levels.	
However,	another	meta-	analysis	(Xu	et	al.,	2014)	included	only	ran-
domized	controlled	trials	comparing	CPAP	therapy	with	sham	CPAP	
or	 control	 groups,	 and	demonstrated	 that	CPAP	 treatment	 signifi-







assigned	 146	 patients	 with	 obesity	 and	 moderate-	to-	severe	 OSA	
to	CPAP	treatment,	weight-	loss,	or	CPAP	plus	weight-	loss	interven-
tion	for	24	weeks,	and	triglyceride	levels	were	significantly	reduced	
in	 the	 weight-	loss	 and	 combined-	intervention	 groups,	 but	 not	 in	
the	 CPAP-	alone	 group.	 The	 effect	 of	 long-	term	CPAP	 therapy	 on	





lipid	 levels	 improved	 following	CPAP	 treatment	 in	 the	 unadjusted	
analysis	 (Gunduz	et	 al.,	 2020).	However,	 after	 adjustment	 for	 age,	
sex,	lipid-	lowering	medication,	change	in	weight,	CPAP	compliance	
and	 duration,	 only	 total	 cholesterol	 levels	 decreased	 significantly	
during	follow-	up	(Figure	5),	and	duration	of	CPAP	therapy	was	the	
only	independent	predictor	for	cholesterol	reduction.	Besides,	coro-
nary heart disease risk assessed by Framingham risk score decreased 
with	CPAP	therapy	in	both	male	and	female	OSA	patients	(Figure	6).
In	 conclusion,	 patients	 with	 OSA	 may	 exhibit	 higher	 rates	 of	
IH-	induced	dyslipidaemia,	a	risk	factor	for	cardiovascular	and	cere-
brovascular	disorders,	and	the	severity	of	OSA	is	correlated	to	the	




correlation	 between	 dyslipidaemia	 and	OSA.	 Also,	 long-	term	 ran-
domized	controlled	trials	with	large	sample	size	and	after	controlling	
confounding factors should be performed to determine the effect of 
CPAP	therapy	on	lipid	levels.
9  |  CONCLUSIONS
Obstructive sleep apnea is a highly prevalent disorder with major 
cardiovascular and metabolic consequences. The relationship 
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between	 OSA	 and	 metabolic	 comorbidities	 is	 bidirectional.	 OSA-	
induced	IH	and	SF	may	result	in	decreased	insulin	sensitivity,	sym-
pathetic	excitation,	and	systemic	inflammation	that	eventually	lead	









microbiota and host metabolism. The gut microbiota composition has 
been	reported	to	associate	with	sleep	disorders	such	as	narcolepsy,	
insomnia	and	OSA.	In	OSA,	IH	and	SF	affect	the	gut	microbiota,	and	
result	 in	 dysbiosis	 and	 health	 consequences.	 Both	 IH	 and	 SF	 due	
to	OSA	may	also	concur	altering	brain	homeostasis	and	producing	
cerebral	 inflammation,	 cognitive	 deterioration,	 neuropsychological	






The	 underlying	 mechanisms	 of	 metabolic	 dysfunction	 in	 OSA	
require	 further	 exploration	 using	 animal	models	 and	 clinical	 data.	
Additionally,	CPAP	is	the	first-	line	treatment	for	OSA,	but	 it	 is	un-
clear	 whether	 CPAP	 treatment	 can	 improve	 metabolic	 disorders.	
Preliminary results of probiotic administration to improve sleep 
quality	in	healthy	volunteers	are	promising,	but	no	data	are	available	
in	patients	with	OSA.	Therefore,	further	studies	are	needed.
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